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Abstract
 
Development of a subunit vaccine for 
 
Mycobacterium tuberculosis
 
 (Mtb) is likely to be dependent
on the identification of T cell antigens that induce strong proliferation and interferon 
 
g
 
 pro-
duction from healthy purified protein derivative (PPD)
 
1
 
 donors. We have developed a sensi-
tive and rapid technique for screening an Mtb genomic library expressed in 
 
Escherichia coli
 
 using
Mtb-specific CD4
 
1
 
 T cells. Using this technique, we identified a family of highly related Mtb
antigens. The gene of one family member encodes a 9.9-kD antigen, termed Mtb9.9A. Re-
combinant Mtb9.9A protein, expressed and purified from 
 
E
 
.
 
 coli
 
, elicited strong T cell prolifer-
ation and IFN-
 
g
 
 production by peripheral blood mononuclear cells from PPD
 
1
 
 but not PPD
 
2
 
individuals. Southern blot analysis and examination of the Mtb genome sequence revealed a
family of highly related genes. A T cell line from a PPD
 
1
 
 donor that failed to react with re-
combinant Mtb9.9A recognized one of the other family members, Mtb9.9C. Synthetic pep-
tides were used to map the T cell epitope recognized by this line, and revealed a single amino
acid substitution in this region when compared with Mtb9.9A. The direct identification of an-
tigens using T cells from immune donors will undoubtedly be critical for the development of
vaccines to several intracellular pathogens.
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Introduction
 
Tuberculosis (TB)
 
1
 
 is the leading cause of mortality among
the infectious diseases afflicting humans, with an estimated
three million deaths annually (1). This alarming statistic has
been compounded in recent years by the emergence of drug-
resistant strains of TB and coinfections with HIV. The
attenuated strain of 
 
Mycobacterium bovis
 
, bacillus Calmette-
Guérin (BCG), is currently the only vaccine for TB approved
for use in humans. Despite its widespread use, BCG has
variable efficacy in human populations (2) and can cause
disseminated disease in immunocompromised individuals.
Thus, the development of an improved TB vaccine is a
high priority from both efficacy and safety viewpoints. One
such approach to achieve this goal is the identification of
immunodominant Mtb antigens that could be incorporated
into a subunit vaccine.
The causative agent of TB, 
 
Mycobacterium tuberculosis
 
(Mtb), is an intracellular pathogen, and as a result the cellu-
lar arm of the immune response predominantly mediates
protective immunity. In particular, CD4
 
1
 
 T cells have been
demonstrated to be critical for containment of Mtb infec-
tion in both mice and humans. In addition, the cytokine
IFN-
 
g
 
 appears to be critical in the development of immu-
nity to TB. Both mice with a disrupted IFN-
 
g
 
 gene and
humans with a mutated IFN-
 
g
 
 receptor are highly suscep-
tible to mycobacterial infections (3–6). Thus, in the devel-
opment of subunit vaccines to Mtb, it is important to iden-
tify immunodominant CD4
 
1
 
 T cell antigens that are capable
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Abbreviations used in this paper: 
 
ATCC, American Type Culture Col-
lection; BCG, bacillus Calmette-Guérin; CFP, culture filtrate protein;
DC, dendritic cell; Mtb, 
 
Mycobacterium tuberculosis
 
; PBS-T, PBS/0.1%
Tween 20; PPD, purified protein derivative; SI, stimulation index; TB,
tuberculosis.  
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of inducing strong IFN-
 
g
 
 responses. A logical source of T
cells to identify such antigens is healthy PPD
 
1
 
 (non–BCG-
vaccinated) donors who presumably have contained their
infection because of protective CD4
 
1
 
 T cell responses.
It is difficult at this time to assess the number and identity
of the immunodominant Mtb antigens that are recognized
by T cells from TB-infected individuals. This is because Mtb
comprises thousands of proteins, and most Mtb antigens
characterized previously were identified using serological re-
agents or by biochemical purification (7–9). However, anti-
gens that induce strong antibody responses are not necessar-
ily the most potent T cell antigens. Moreover, most of the
CD4
 
1
 
 T cell clones derived from PPD
 
1
 
 donors do not react
with previously identified Mtb antigens, such as the antigen
85 family or heat shock protein 65 (10). Various biochemical
purification techniques have been developed to identify anti-
gens directly using T cells, including T cell blotting (11). Al-
though these approaches have met with some success with
the identification of antigens such as 6-kD early secretory an-
tigenic target (ESAT-6 [12]) and Mtb8.4 (13), it is likely that
there are T cell antigens not easily identified by this method-
ology because of low expression in Mtb preparations, mak-
ing them difficult to purify to homogeneity.
To overcome the potential difficulties in identifying T cell
antigens by their purification, as described above, we have
developed a rapid, simple, and sensitive technique for the
identification of antigens that have been cloned from Mtb
into an 
 
Escherichia coli
 
 expression library using T cells from
healthy PPD
 
1
 
 donors. These donors have been infected
with Mtb and were able to control the infection, and are
therefore a good source of T cells that are presumably reac-
tive with protective antigens. In this study, we have used T
cells from one such donor to isolate a family of genes from
Mtb, and have subsequently demonstrated that one member
of this family is recognized by T cells from the majority of
healthy PPD
 
1
 
 individuals. As such, these antigens may be
important for the development of a subunit vaccine for Mtb.
 
Materials and Methods
 
Bacterial Strains. 
 
Mtb
 
 
 
strains H37Rv and Erdman were gifts
from the Seattle Veterans Administration Hospital. Mtb “C”
strain was a gift from Dr. Lee Riley (University of California at
Berkeley, Berkeley, CA); 
 
Mycobacterium bovis
 
 BCG and 
 
Mycobacte-
rium leprae
 
 were obtained from Genesis Corporation, and the fol-
lowing mycobacterial strains were obtained from American Type
Culture Collection (ATCC): 
 
M
 
.
 
 vaccae
 
 (ATCC 15483), 
 
M
 
.
 
 avium
 
(ATCC 35718), 
 
M
 
.
 
 chelonae
 
 (ATCC 14472),
 
 M
 
.
 
 fortuitum
 
 (ATCC
6841), 
 
M
 
.
 
 gordonae
 
 (ATCC 14470), 
 
M
 
.
 
 scrofulaceum
 
 (ATCC 19981),
and 
 
M
 
.
 
 smegmatis
 
 (ATCC 19420).
 
Generation of Mtb-specific T Cell Lines from PPD
 
1
 
 Donors.
 
PBMCs
were obtained from the apheresis product of healthy PPD
 
1
 
 do-
nors by density centrifugation over Ficoll. HLA typing was per-
formed at the Puget Sound Blood Center (Seattle, WA). Donor
160 is a health care worker who became PPD skin test positive
after exposure to a patient with TB and is HLA-DR13, 15 and
HLA-DQ1, 7. Other donors used in this study were HLA typed
as follows. Donor 7: HLA-DR13, 15, HLA-DQ1; donor 103:
HLA-DR4, 15, HLA-DQ1, 3; donor 184: HLA-DR4, 7, HLA-
 
DQ2, 4; and donor 201: HLA-DR3, HLA-DQ2. Dendritic cells
(DCs) were generated by culture of autologous adherent PBMCs
with GM-CSF and IL-4 for 7 d as described (14). DCs were in-
fected with Mtb by overnight culture at a multiplicity of infec-
tion of 10 as described (15). Mtb-infected DCs were cultured at
10
 
4
 
 cells per well in 96-well round-bottomed plates with varying
numbers of monocyte-depleted PBMCs as responder cells (10
 
2
 
–
10
 
4
 
). Wells that showed obvious growth of T cells were then ex-
panded with CD3 antibody and tested for reactivity with culture
filtrate proteins (CFPs) from Mtb (provided by Dr. John Belisle,
Colorado State University, Fort Collins, CO; produced through
National Institutes of Health, National Institute of Allergy and
Infectious Diseases Tuberculosis Research Materials contract N01
AI-25147), using autologous PBMCs as APCs. The T cell lines
used in this study (DC-4 and DC-6) were from wells plated at
10
 
3
 
 lymphocytes per well, and at this seeding density were pre-
dicted to be oligoclonal.
 
Construction and Screening of an Mtb Expression Library. 
 
Mtb
Erdman genomic DNA was isolated and sheared by sonication to a
size range of 1–4 kb. H37Rv genomic DNA was partially digested
with Sau3A and was size fractionated. Libraries were constructed in
Lambda ZapII (Stratagene) as described (13). Both phage libraries
were excised according to the manufacturer’s protocol, using 
 
z
 
10
 
6
 
recombinant phages. Transfected bacteria were plated to give
 
z
 
50–80 transfectants per plate, and colonies were pooled to estab-
lish glycerol stocks. The glycerol stocks were used to establish
overnight cultures (2XYT/100 
 
m
 
g/ml ampicillin) that were split
1:5 or 1:10 the next morning. Plates were grown for an additional
1 h and then induced by the addition of isopropyl-
 
b
 
-
 
d
 
-thio-galac-
topyranoside (IPTG). After induction for 3–4 h, plates were centri-
fuged and the supernatant was discarded. Bacterial pellets were re-
suspended in 200 
 
m
 
l antibiotic-free RPMI/10% FCS, and 10 
 
m
 
l
was added in duplicate to wells containing DCs, also plated in anti-
biotic-free medium. The plates were cultured for 90 min at 37
 
8
 
C
and washed to remove excess bacteria. The medium was replaced
with antibiotic-containing complete medium (RPMI/10% pooled
human serum/50 
 
m
 
g/ml gentamicin), and 10
 
4
 
 T cells were added.
The plates were cultured for an additional 3 d, after which 50 
 
m
 
l
was removed for assessment of IFN-
 
g
 
 by ELISA, and the plates
were pulsed with tritiated thymidine (1 
 
m
 
Ci per well). After cul-
ture for an additional 18 h, cells were harvested and tritium uptake
was determined using a gas scintillation counter. IFN-
 
g
 
 levels in
culture supernatants were determined by ELISA as described (15).
 
Expression of rMtb9.9A. 
 
Clone TB46R10C10, isolated from
pool 46, was used as a template to PCR amplify the region encod-
ing 
 
mtb9
 
.
 
9A
 
. The 5
 
9
 
 primer was designed to include an NdeI site,
which also contained the starting ATG, followed by residues en-
coding an NH
 
2
 
-terminal six-histidine tag. The 3
 
9
 
 primer included
a HindIII site following the residues encoding the termination
codon. Amplified product was digested with NdeI and HindIII and
ligated into pET17b. This clone was referred to as pETMtb9.9A,
and the recombinant protein encoded as rMtb9.9A.
Expression and purification of rMtb9.9A was performed essen-
tially as described for other Mtb proteins (16). In brief, induced
 
E
 
.
 
 coli
 
 BL-21 (pLysE) pellets were lysed, and the recombinant pro-
teins were recovered in the inclusion bodies. Purification was via
affinity chromatography on an Ni
 
2
 
1
 
 nitrilotriacetic acid (NTA)-
agarose column. Purity of the recombinant protein was assessed
by SDS-PAGE, followed by Coomassie blue staining and then
NH
 
2
 
-terminal sequencing using traditional Erdman chemistry with
a Procise
 
® 
 
494 protein sequencer (Perkin Elmer/Applied Biosys-
tems). Endotoxin was determined to be 
 
,
 
100 EU/mg of protein
by the 
 
Limulus
 
 amebocyte lysate (LAL) assay (BioWhittaker). 
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Engineering, expression, and purification of rMtb 85B were
performed as described (16).
All DNA manipulations of the various clones were confirmed
by DNA sequencing to eliminate the possibility of the introduc-
tion of mutations by restriction, ligation, and PCR.
 
Mtb9.9 Peptide Synthesis. 
 
Peptides derived from the predicted
amino acid sequences from the 
 
mtb9
 
.
 
9
 
 gene family were synthesized
on a Rainin/PTI Symphony peptide synthesizer using 9-fluorenyl-
methoxycarbonyl batch chemistry with 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate activation. Pep-
tides were analyzed by reverse phase HPLC using a Vydac C18
column. Peptide molecular masses were verified using a matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF)
mass spectrometer.
 
Molecular Analysis of Mtb Clones. 
 
DNA was prepared accord-
ing to the manufacturers’ protocols (Qiagen and Promega). DNA
sequencing was performed using an Applied Biosystems Auto-
mated Sequencer (model 373). DNA sequences and deduced
amino acid sequences were used in database searches (GenBank
nonredundant DNA and protein databases). The Mtb H37Rv
nucleotide sequences of 
 
mtb9
 
.
 
9a
 
, 
 
mtb9
 
.
 
9c
 
, 
 
mtb9
 
.9d, and mtb9.9e
are available from GenBank under accession nos. CAA17714,
CAB07821, CAB06842, and CAB06161, respectively. The Mtb
Erdman nucleotide sequence of mtb9.9b is available from Gen-
Bank under accession no. AF226277.
Genomic DNA from mycobacterial strains was digested with
PstI, separated by agarose gel electrophoresis, and blotted on Ny-
tran® (Schleicher & Schuell). The mtb9.9a gene was labeled with
[32P]dCTP by random oligonucleotide primers (Boehringer Mann-
heim) and used as a probe. Hybridization was performed at 658C in
0.2 M NaH2PO4, 3.6 M NaCl, 0.2 M EDTA overnight and
washed to a stringency of 0.075 M NaCl, 0.0075 M C6H5Na3O7,
pH 7.0, 0.5% SDS at the temperature of hybridization.
Immunoblot Analysis.  Antisera to rMtb9.9A and r85B were
raised using adult New Zealand white rabbits (R & R Rabbitry)
by an initial subcutaneous immunization of 200 mg of recombi-
nant antigen in 1 ml IFA and 100 mg muramyl dipeptide (Calbi-
ochem), followed by two successive subcutaneous immunizations
of 100 mg antigen in 1 ml IFA at 3-wk intervals. A final intrave-
nous boost of 100 mg antigen was delivered after another 4 wk,
and serum was collected 2 wk later.
Mtb H37Rv lysate, CFPs, and purified rMtb9.9A were sub-
jected to SDS-PAGE and transferred to nitrocellulose. Filters were
blocked with PBS containing 5% nonfat dried milk at 48C over-
night, washed three times in PBS/0.1% Tween 20 (PBS-T), and
incubated for 1 h in rabbit sera (1:250 in PBS-T) on a rocker at
room temperature. Filters were washed three times with PBS-T,
and bound antibody was detected with 105 cpm/ml 125I-labeled
protein A, followed by autoradiography.
Proliferation and IFN-g Assays.  PBMCs from PPD1 and PPD2
donors were cultured in complete medium in 96-well round-bot-
tomed plates (Corning Costar) at 2 3 105 cells per well in a vol-
ume of 200 ml. After 5 d of culture at 378C in 5% CO2, 50 ml of
culture supernatant was removed for determination of IFN-g lev-
els, and the plates were pulsed with tritiated thymidine as described
above. Data are presented as the mean of triplicate cultures.
Results
Recognition of E. coli–expressed Antigen by T Cells.  To es-
tablish the feasibility of detecting Mtb antigens expressed in
E. coli, we used a T cell clone of known specificity for an
Mtb antigen, Mtb11, identified previously in our laboratory
(Dillon, D.C., M.R. Alderson, C.H. Day, T. Bement, A.
Campos-Neto, Y.A.W. Skeiky, T. Vedvick, R. Badaro, S.G.
Reed, and R. Houghton, manuscript in preparation). This T
cell clone, 4E4, proliferated and produced IFN-g in response
to rMtb11 and CFPs derived from Mtb. 4E4 T cells were as-
sessed for their ability to recognize whole E. coli expressing
the Mtb11 antigen. E. coli expressing either Mtb11 or vector
alone were incubated with either autologous DCs or autol-
ogous macrophages for 90 min under antibiotic-free condi-
tions. Nonphagocytosed and nonbound E. coli were then
washed away and replaced with medium containing gentami-
cin to kill remaining free bacteria. 4E4 T cells were then
added and cultured for an additional 72 h before assay for
IFN-g production. As shown in Fig. 1, 4E4 cells produced
IFN-g in response to E. coli expressing Mtb11 but not E. coli
expressing vector alone. In addition, the responses using DCs
as APCs were far stronger than with macrophages. The data
also demonstrate that the E. coli expressing Mtb11 could be
Figure 1. Responses of Mtb11-specific T cell clone (4E4) to either puri-
fied rMtb11 or varying numbers of E. coli expressing either vector alone or
rMtb11. 104 4E4 cells were cultured for 3 d with either (A) 104 autologous
macrophages or (B) 104 autologous monocyte-derived DCs that had been
incubated with either E. coli or purified rMtb11. Supernatants were assessed
for IFN-g levels by ELISA. The highest concentrations of E. coli and
rMtb11 were z106 bacteria per well and 10 mg/ml, respectively.554 T Cell Expression Cloning of M. tuberculosis Antigens
diluted out as far as 1:1,000 (z103 bacteria per well) and still
induce strong antigen-specific IFN-g production.
Generation of T Cell Lines to Mtb Antigens.  Having estab-
lished that  E. coli–expressed antigens could be presented to
T cells efficiently by monocyte-derived DCs, we attempted
next to determine whether this technique could be used to
identify novel Mtb antigens. We have established a panel of
PBMCs from healthy PPD1 individuals with no history of
TB as a source of Mtb-reactive T cells. Because these indi-
viduals were most likely infected with Mtb, but did not de-
velop TB, they have presumably acquired a protective im-
mune response, and as such their T cells are predicted to
recognize protective antigens. Furthermore, to bias the T
cells towards antigens expressed by Mtb-infected cells
rather than antigens that may be overexpressed in broth
cultures of Mtb, we generated T cell lines to autologous
blood-derived DCs that had been infected with Mtb. We
and others have shown previously that these DCs are ame-
nable to infection with Mtb and are extremely potent APCs
(15, 17). Limiting dilution techniques were used to estab-
lish Mtb-reactive T cell lines that were subsequently
screened for reactivity with CFPs and a panel of rMtb anti-
gens. The reactivity of two such T cell lines, DC-4 and DC-6,
which were established from a recent PPD converter (do-
nor 160), is shown in Fig. 2. The DC-4 cell line showed
strong reactivity with CFPs and rMtb39A (16) but not with
any of the other recombinant antigens, whereas DC-6 re-
acted strongly with CFPs and Mtb11 and weakly with
Mtb39A. In addition, DC-6 but not DC-4 reacted strongly
with whole E. coli expressing Mtb11 (Fig. 2 B). We chose
to use the DC-6 line to screen an expression library to try
and identify the Mtb11 and Mtb39A genes as a test of the
system (proof of principal), as well as to identify potentially
novel Mtb genes due to the established oligoclonal nature
of the T cell line.
Isolation of a Novel Family of T Cell–stimulating Mtb Anti-
gens by Expression Cloning.  To screen for novel Mtb T
cell antigens, we constructed a genomic Mtb library in the
pBSK expression vector (see Materials and Methods). Based
on the data shown in Figs. 1 and 2, we chose to screen
pools of 50–80 recombinants using the DC-6 T cell line
and autologous DCs as APCs. The data obtained from the
screening of 48 pools of recombinants in duplicate are
shown in Fig. 3, A and B. Six pools (6, 8, 29, 32, 34, and
46) elicited strong proliferation and IFN-g responses, and
two pools (37 and 47) gave weak but positive responses.
Similar data were obtained when these pools were screened
with the DC-4 T cell line (data not shown). Individual col-
onies were generated from the positive pools, and the assay
Figure 2. Reactivities of donor 160 DC-4 and DC-6 T cell lines gen-
erated to autologous DCs infected with Mtb to (A) purified rMtb anti-
gens (10 mg/ml) and (B) E. coli expressing rMtb11 either neat or diluted
1:25 in control E. coli.
Figure 3. Screen of 48 pools of z50–80 recombinants per pool from
Mtb Erdman library with donor 160 DC-6 T cell line. Data are the mean
of duplicate wells. (A) Proliferation. (B) IFN-g. (C) Confirmation of sin-
gle positive clone derived from pool 31.555 Alderson et al.
was repeated with less complex pools until single recombi-
nant positive clones were identified. Single recombinants were
assayed an additional time to confirm that they were indeed
positive (Fig. 3 C), and the DNA inserts were sequenced.
Single recombinant clones were successfully identified in
six of the eight positive pools. Two of the single recombi-
nants contained fragments of the previously identified
Mtb39A antigen (Table I). The other four clones contained
three distinct open reading frames that were highly homol-
ogous with one another and were predicted to encode 94
amino acid proteins of molecular mass of 9.9 kD, and were
therefore designated Mtb9.9A, Mtb9.9B, and Mtb9.9C.
Subsequent screening of additional pools also identified a
fourth family member, designated Mtb9.9D, and the Mtb11
gene (data not shown).
Synthetic Peptides Generated Using the mtb9.9a Gene Sequence
and Purified rMtb9.9A Stimulate DC-6 Cells.  To establish
conclusively that the mtb9.9 genes were responsible for
stimulation of the DC-6 T cell line, we synthesized pep-
tides (15 amino acids that overlapped by 10 amino acids)
corresponding to the protein sequence predicted to be en-
coded by the mtb9.9a gene. As shown in Fig. 4 A, peptides
2 and 3 from Mtb9.9A stimulated a strong response in the
DC-6 T cell line. The overlapping sequence between these
two peptides contained the amino acid sequence DAH-
GAMIRAQ. In addition, the mtb9.9a gene was subcloned
into the pET17b expression plasmid (Novagen), and the
recombinant protein was expressed and purified (data not
shown). Purified rMtb9.9A also stimulated a strong response
in the DC-6 line (Fig. 4 B).
Characterization of the Mtb9.9 Genes and Proteins.  To fur-
ther characterize the mtb9.9 gene family, Southern blot
analysis was performed on a variety of mycobacterial strains
using the mtb9.9a gene as a probe (Fig. 5). The data dem-
onstrated the presence of a highly related gene family con-
taining between three and five members within different
isolates of Mtb, including two from clinical sources. The
Table I. Identity of Isolated Recombinants from Positive Pools 
Detected by T Cell Line Donor 160 DC-6
Pool no. Identity
6 Novel gene, termed mtb9.9b
8 Novel gene, termed mtb9.9c
29 Unable to identify reactive gene
32 mtb39 NH2 terminus
34 Novel gene, termed mtb9.9a
37 Unable to identify reactive gene
46 Novel gene, termed mtb9.9a
(overlaps with clone in pool 34)
47 mtb39 COOH terminus
Figure 4. Responses of donor 160 DC-6 T cell line to either (A) syn-
thetic peptides generated from Mtb9.9A (10 mg/ml) or (B) rMtb9.9A.
Figure 5. Southern blot analysis of Mtb9.9 genes. Genomic DNA from
various mycobacterial strains was digested with PstI, separated by agarose
gel electrophoresis, and blotted on Nytran®. The mtb9.9a gene was la-
beled with 32P and used as a probe. Size markers (M) are in kb. 556 T Cell Expression Cloning of M. tuberculosis Antigens
data also indicate that these genes are well conserved in M.
bovis BCG, but significantly less conserved or absent in all
other mycobacterial species tested.
Examination of the Mtb H37Rv genome sequence (18)
revealed four mtb9.9 gene family members, including three
that we had isolated from the Erdman strain. The H37Rv
genome did not contain the mtb9.9b form that we isolated
from the Erdman library, but did contain an additional
form that was designated mtb9.9e. A comparison of the pre-
dicted amino acid sequences encoded by the five mtb9.9
genes is shown in Fig. 6. Interestingly, it was observed that
mtb9.9c is located near mtb39a (16), a member of a gene
family encoding a potent T cell antigen also recognized by
DC-6 cells (Table I).
Purified rMtb9.9A was used to generate a high titer rab-
bit antiserum that was used for Western blot analysis of the
native Mtb9.9 protein. As demonstrated in Fig. 7, Mtb9.9
protein is predominantly located in the cell fraction of Mtb,
with low but detectable quantities in the culture filtrate of
Mtb. As a control, a rabbit antiserum to antigen 85B
showed abundant expression of this protein in both Mtb
lysate and CFPs (Fig. 7 C).
Response of PBMCs from PPD1 and PPD2 Donors to
rMtb9.9A.  rMtb9.9A was next assessed for its ability to
stimulate T cell proliferation and IFN-g production from a
panel of PBMCs derived from normal PPD2 and healthy
PPD1 donors, including those of donor 160, from which
the Mtb9.9-reactive T cell line (DC-6) was generated. Us-
ing a stimulation index (SI) of 5 as a measure of a positive
response, 10/12 (83%) of the PPD1 donors responded to
rMtb9.9A compared with 8/12 (67%) that responded to re-
combinant antigen 85B (Fig. 8). In addition, the magnitude
of the responses to rMtb9.9A was very strong (mean SI
39.0) compared with antigen r85B (mean SI 15.3). All 12
of the PPD1 donors made a significant response to CFPs.
Of the PPD2 donors, 0/12 responded to rMtb9.9A com-
pared with 2/12 that responded to antigen r85B, suggesting
that rMtb9.9A has greater specificity for Mtb infection than
r85B. rMtb9.9A also induced strong IFN-g responses in
the majority of the PPD1 donors (Fig. 8).
Response of PBMCs from PPD1 Donors to Overlapping Syn-
thetic Peptides Derived from the Mtb9.9A, Mtb9.9B, and
Mtb9.9C Sequences.  Four donors that made strong re-
sponses to rMtb9.9A were selected for epitope mapping
studies of their T cell responses to peptides derived from
the Mtb9.9 gene family sequences. Donor 160 PBMCs re-
sponded predominantly to the number 2 and 3 peptides, in
agreement with the reactivity of the DC-6 T cell line gen-
erated from this donor. Donor 7 PBMCs responded weakly
to peptides 2 and 3, and made a strong response to peptide 6
from Mtb9.9A and Mtb9.9C, but not from Mtb9.9B. Do-
nor 103 PBMCs responded primarily to peptides 12 and
13, whereas PBMCs from donor 184 responded to peptides
14 and 15. Collectively, these data suggest that there is a
minimum of four T cell epitopes contained within the
Mtb9.9 sequences.
Identification of an Mtb9.9C-specific T Cell Line.  We next
generated a T cell line from donor 201, whose PBMCs
failed to react with rMtb9.9A. This T cell line was used to
screen the same pools as were screened with the DC-6 line.
Interestingly, the only positive pool detected using the do-
nor 201 T cell line with autologous DCs as APCs was
number 8, which was known to contain the mtb9.9c gene.
Despite showing strong reactivity with pool 8, this T cell
line failed to react with other pools known to contain
mtb9.9a and mtb9.9b genes (pools 6, 34, and 46). This sug-
gested that either this T cell line reacted with a novel clone
contained within pool 8, or it reacted with Mtb9.9C but
not Mtb9.9A or Mtb9.9B. To test the latter hypothesis, we
assessed the donor 201 line for reactivity with the synthetic
peptides derived from the Mtb9.9 sequences. This T cell
line reacted only with peptides 3 and 4 from Mtb9.9C, and
not with either rMtb9.9A or peptides derived from Mtb9.9A
Figure 6. Predicted amino acid sequence of Mtb9.9 proteins. (A)
Comparison of the predicted amino acid sequences of the five Mtb9.9
family members, and (B) overlapping synthetic peptides generated com-
prising portions of these sequences (peptides derived from Mtb9.9A de-
noted by number only). The Mtb H37Rv nucleotide sequences of
mtb9.9a, mtb9.9c, mtb9.9d, and mtb9.9e are available from GenBank under
accession nos. CAA17714, CAB07821, CAB06842, and CAB06161, re-
spectively. The Mtb Erdman nucleotide sequence of mtb9.9b is available
from GenBank under accession no. AF226277.
Figure 7. Western blot analysis of Mtb9.9 protein. The blots were
probed with (A) preimmune rabbit serum, (B) antiserum to rMtb9.9A, and
(C) antiserum to antigen r85B. Mtb lysate and CFPs were run at 5 mg/
lane and rMtb9.9A at 50 ng/lane.557 Alderson et al.
or Mtb9.9B (see Fig. 10). Interestingly, the peptide sequence
for this region (the overlap between peptides 3 and 4) only
differs by two amino acids between Mtb9.9C and Mtb9.9A,
and one amino acid between Mtb9.9C and Mtb9.9B (Fig. 6).
Discussion
The identification of antigens from Mtb that stimulate
CD41 T cells has been hampered in the past by the use of
techniques that relied on non–T cell components of the
immune response for their identification. For example, the
majority of Mtb antigens characterized thus far were origi-
nally identified based on their reactivity with antibodies, or
as a consequence of their abundance and subsequent ease
for purification (7–9). The potential problem with these
approaches is that antigens that stimulate potent T cell re-
sponses are not necessarily the same as those that stimulate
strong antibody responses, nor are they necessarily the most
abundant antigens. Indeed, of five Mtb antigens that we re-
cently isolated using human serum from patients with TB,
only one induced strong T cell responses in PPD1 donors
(16). The technique we describe in this paper minimizes this
problem because it uses T cells to directly identify antigens
that are expressed as recombinant antigens in E. coli.
Previous studies have demonstrated that antigenic pro-
teins expressed by recombinant E. coli can be presented by
class II MHC molecules to antigen-specific T cells (19). In-
deed, Shastri and colleagues (20, 21) demonstrated that this
property of E. coli–expressed antigens could be applied to
identify two previously unknown antigens from Listeria
monocytogenes using murine CD41 T cells. This technique
relied on the fusion of the antigen-specific T cells with a
hybridoma partner containing a reporter gene (lacZ), and
on screening for T cell activation at the single cell level.
The technique we describe in this paper is much simpler and
is amenable to high throughput screening, as it can be used
with either T cell clones or lines, and does not require the
generation of either hybridomas or a single cell assay. By
taking advantage of the fact that blood-derived DCs are both
phagocytic and are extremely potent APCs (17), we were
able to use an antigen-reactive T cell line to detect a previ-
ously identified Mtb antigen (Mtb39 [16]), as well as a fam-
ily of previously unknown Mtb antigens (the Mtb9.9 fam-
ily). In addition, we have used T cells from a TB-immune
human donor, which presumably has relevance for the de-
velopment of human vaccines.
Several antigens derived from Mtb have been reported
to stimulate T cell responses from Mtb-infected humans
and mice. In particular, the antigen 85B has been reported
to be an immunodominant T cell antigen (22). Here, we
show that upon preliminary analysis, rMtb9.9A appears to
be a more potent T cell antigen than antigen r85B. Of the
12 PPD1 donors tested, 10 made a significant proliferative
response to rMtb9.9A (83%) compared with 8 who re-
sponded to r85B (67%). In particular, the magnitude of the
responses to rMtb9.9A was stronger than to r85B, such that
the mean SI with rMtb9.9A from PPD1 donors was 39.0
compared with 15.3 with r85B. Finally, rMtb9.9A induced
strong IFN-g responses in PPD1 but not PPD2 donors,
further implicating Mtb9.9A as a candidate for inducing
protective immune responses to Mtb.
The use of APCs infected with live Mtb to generate T
cell lines ensures that the antigens that are detected are
available to the immune response during infection with
Mtb. Interestingly, Mtb9.9 was found to be primarily lo-
cated in Mtb lysate, although low levels of protein were
detected in CFPs by Western blotting. However, the
quantity of Mtb9.9 in CFPs was sufficient to stimulate T
Figure 8. Response of PBMCs from (A
and C) 12 healthy PPD1 and (B and D) 12
normal PPD2 donors to rMtb9.9A. A and B
show proliferation data; C and D show
IFN-g data. CFPs, r85B, and rMtb9.9A
were used at 10 mg/ml, and Tetanus Tox-
oid (Tet Tox) was used at 0.1 LP/ml.558 T Cell Expression Cloning of M. tuberculosis Antigens
cell responses, as the donor 201 line that reacted with
Mtb9.9C was generated using CFPs as antigen. This high-
lights the sensitivity of the expression cloning technique, as
it was able to identify an antigen present at low levels within
a complex mixture of proteins. Indeed, rMtb9.9A is able to
stimulate T cell responses at extremely low protein concen-
trations, with as little as 10 ng/ml resulting in optimal recall
responses (Fig. 4 B), and as little as 100 pg/ml able to stimu-
late responses above background (data not shown).
Several groups have reported a heterogeneous response
to Mtb antigens among healthy PPD1 individuals and pa-
tients with TB (10, 23). Interestingly, Boesen et al. (24) de-
scribed preferential recognition of low-mass CFPs in the
majority of patients with minimal TB. This fraction con-
tains several proteins, including 6-kD early secretory anti-
genic target, Mtb8.4, and Mtb9.9A. Although the Mtb9.9
family of proteins is of low mass, they were found to con-
tain at least five distinct T cell epitopes (Figs. 9 and 10). In
addition, the donors used in this study represented a variety
of ethnic backgrounds and HLA types. This may be impor-
tant in the design of a subunit vaccine for Mtb, where T
cell responses to antigens presented by a large number of
MHC alleles would be required to vaccinate the majority
of humans. In addition, most PPD1 donors (.80%) made a
T cell response to rMtb9.9A, again suggesting that immu-
nization of an outbred human population could potentially
induce responses in the vast majority of individuals. Indeed,
in preliminary studies, immunization of inbred mice and
outbred guinea pigs with rMtb9.9A induced strong anti-
gen-specific T cell responses (data not shown).
Despite the very high amino acid homology among the
members of the Mtb9.9 family, we observed heterogeneity
in the T cell response to each of the antigens. For example,
T cells from donor 201 were found to react only with pep-
tides from Mtb9.9C and not Mtb9.9A or Mtb9.9B. In ad-
dition, PBMCs from donor 7 only responded to peptide 6
from Mtb9.9A and Mtb9.9C but not from Mtb9.9B.
Whether this represents a means for Mtb to evade the im-
mune system by antigenic drift remains to be investigated.
In conclusion, we have developed a very simple and sen-
sitive expression cloning strategy for identifying antigens that
are recognized by CD41 T cells. Such a strategy is likely to
be applicable to the identification of CD41 T cell antigens
from other infectious disease microorganisms, as well as an-
tigens from other sources.
Figure 9. Response of PBMCs from four
PPD1 donors to rMtb9.9A and overlapping
synthetic peptides derived from Mtb9.9A,
Mtb9.9B, and Mtb9.9C sequences (peptides
derived from Mtb9.9A denoted by number
only). Peptides and rMtb9.9A were used at 10
mg/ml.
Figure 10. Response of donor 201 T cell line to rMtb9.9A and
Mtb9.9A, Mtb9.9B and Mtb9.9C peptides (10 mg/ml).559 Alderson et al.
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